

Press release

Heraeus Kulzer: What is new for the dentist Strengthen efficient dental practice workflows

Hanau, 9th March 2015 – **When the IDS opens its doors, the international dental industry will seek answers for the challenges of tomorrow. Heraeus Kulzer presents integrated materials, technologies and services that organise the workflows in the dental practice more efficiently.**

With a completely new, inviting trade fair appearance, Heraeus Kulzer presents innovations for safe and efficient workflows in the dental practice. "We want to reduce the complexity and ease the lives of our users", explains Novica Savic, head of the Dental Materials division at Heraeus Kulzer.

Safe materials for reliable results

With the new **iBOND® Universal**, Heraeus Kulzer presents a universal bonding material for direct and indirect restorations, suitable for several different surfaces and materials, at the IDS. In everyday practice, it creates space in the material storage room and reduces application errors. The user can rely on the excellent adhesion during all indications. The new dropper with "drop control" facilitates extremely precise dosing and prevents the unnoticed escape and adhesion of fluid. In future, all iBOND and GLUMA bottles will be furnished with this technology. New labels on the **Venus® Diamond** and **Venus® Pearl** PLTs improve the readability with unique colour codes, and make the shade and composite selection easier.

Press Contact

Nina Mautner
Manager Corporate Communications
Heraeus Kulzer GmbH

Gruener Weg 11
D-63450 Hanau

Phone: +49 (0) 6181/35 3162
nina-katrin.mautner@kulzer-dental.com
www.heraeus-kulzer.com

Heraeus Kulzer in Social Media



About Heraeus Kulzer

Heraeus Kulzer GmbH is one of the world's leading dental companies with its headquarters in Hanau, Germany. As a trusted partner, the company supplies dentists and dental technicians with an extensive product range, covering cosmetic dentistry, tooth preservation, prosthetics, periodontology and digital dentistry. More than 1,400 employees at 25 locations worldwide are driven by their expertise and passion for the dental market and embody what the name Heraeus Kulzer stands for: service, quality and innovation. In 2013 Heraeus Kulzer's product turnover exceeded 400 million USD.

Heraeus Kulzer has been part of the Japanese Mitsui Chemicals Group since July 2013. Mitsui Chemicals Inc. (MCI) is based in Tokyo, and has 135 affiliates with more than 14,200 employees in 27 countries worldwide. Its innovative, practical chemical products are as much in demand in the automotive, electronics and packaging industries as they are in other fields such as environmental protection and healthcare.

The improved formula of the proven universal composite **Charisma**[®] ensures long-lasting natural results with even more ease of application. The newly added ceramic fillers enable vital shades and increase the chameleon effect.

The local antibiotic **Ligosan**[®] **Slow Release**, introduced in Germany in 2010, continues its successful course to the IDS: Since 2013, it has been authorised in large parts of the EU under the name of Ligosan or Adjusan or Ligoslo. For this reason, patients outside of Germany also profit from the supporting therapy during chronic and aggressive periodontitis. Because it is administered as a gel, the active ingredient doxycycline is released into the periodontal pockets for the duration of a minimum of twelve days.

Use digital options

"We support dentists in digital prosthetics with our integrated CAD/CAM system, cara", explains Dr Andreas Bacher, head of the Dental Services division at Heraeus Kulzer. An innovation at the IDS is the **cara YantaLoc**[®] retention element for partial and full dentures: Through the connection comprising a screwed implant base with an angulated zirconia retainer featuring a Locator[®] function, users can safely and flexibly fix the removable dental restorations. The retention element is adhered to the titanium base in the laboratory, and screwed on at the dental practice, thus minimising the risk of peri-implantitis. The smooth zirconia surface means the matrix inserts retain their friction for longer: This makes frequent replacement unnecessary. As with the **cara I-Bridge**[®], the **cara I-Bar**[®] and the **cara I-Butment**[®], an angulation of up to 20 degree ensures flexibility during design and ensures aesthetic results. Heraeus Kulzer holds the patent for manufacturing the angulated screw channel in implant superstructures.

Tips and trends at the IDS booth

At the Heraeus Kulzer **IDS booth**, dentists can experience innovation. Among other things, they can convince themselves of the bonding strength of the new iBOND Universal during a test. Leading dentists give tips about efficient use of

the materials and technologies. A highlight in the official **Speakers' Corner** of the IDS is the talk by Prof Dr Ralf Smeets on the 12th of March about the prophylaxis and therapy of peri-implantitis in implant prosthetics.

In the **Future Corner**, visitors take a look into the future together with Heraeus Kulzer. At the cara section of the booth, participants can experience the cara production centre using 3D Oculus Rift glasses.

Illustrations



Fig. 1: The new universal bonding iBOND® Universal is suitable for direct and indirect restoration as well as for several different surface and materials.



Fig. 2: The new labels on Venus® Diamond and Venus® Pearl PLTs improve the readability and facilitate the immediate identification of composite and shade.




Fig. 3: The zirconia retaining element cara YantaLoc® is available in five different angulations of up to 20 degrees.

(Images released for use in print and online media, photo credits: ©Heraeus Kulzer)

(Locator® and Zest® are registered trademarks of Zest IP Holdings, LLC, 92029, Escondido, USA)

You can find further information about IDS, the company Heraeus Kulzer and its products at www.heraeus-kulzer.com, on YouTube at www.heraeus-kulzer.com/youtube or directly at the **IDS in Hall 10.1 at booth A010 – C019**.

© 2015 Heraeus Kulzer GmbH. All rights reserved. "Heraeus" is a registered trademark of Heraeus Holding GmbH used under a temporary licence granted by Heraeus Holding GmbH. Neither Heraeus Holding GmbH nor any of its affiliates is responsible for the manufacturing of the product(s).

PHARMACEUTICAL INFORMATION

Ligosan Slow Release, 140 mg/g, periodontal gel for the treatment of periodontitis, active substance: Doxycycline

Composition: 1 single-application cylindrical cartridge contains 260 mg of Ligosan Slow Release.

Active agent: 1 g of Ligosan Slow Release contains 140.0 mg of doxycycline corresponding to 161.5 mg of doxycycline hyclate. Other excipients: Polyglycolide, Macrogol-DL-lactide/glycolide copolymer (high viscosity), Macrogol-DL-lactide/glycolide copolymer (low viscosity).

Therapeutic indications: For the treatment of chronic, aggressive periodontitis with a pocket depth of ≥ 5 mm in adults as an adjunct to conventional non-surgical periodontitis.

Contraindications: Where there is known hypersensitivity to doxycycline, other tetracycline antibiotics or one of the other excipients of Ligosan Slow Release; in patients who have been given systemic antibiotics before or during the periodontal therapy; during odontogenesis (during early childhood and during childhood up to the age of 12 years); during pregnancy; in patients with an increased risk of acute porphyria; in patients with a severely restricted liver function.

Side effects: After treatment with Ligosan Slow Release the frequency and nature of side effects were comparable with the side effects after traditional periodontitis treatment.

Uncommon side effects are: Swelling of the gingiva (periodontal abscess), chewing-gum like taste when the gel comes out of the gingival pocket. As it has been proven that the application of Ligosan Slow Release only leads to very low doxycycline plasma concentrations, the occurrence of systemic side effects is very unlikely. General disorders and administration site conditions: Hypersensitivity reactions, urticaria, angioneurotic oedema, anaphylaxis, anaphylactic purpura. There is complete cross sensitivity within the tetracycline antibiotic group. In rare cases irreversible tooth discolouration and dental enamel damage have been observed when administering doxycycline to children while their teeth are developing.

Prescription only medicine.

Market authorisation holder and manufacturer: Heraeus Kulzer GmbH, Grüner Weg 11, 63450 Hanau

Date of revision of text: 07/2013